Periti P, Mini E. Drug resistance in cancer: an overview of the clinical aspects. J Chemother 1989; 1: 5-9.Periti P, Mini E (1989) Drug resistance in cancer: an overview of the clinical aspects. J Chemother 1:5P. Periti, and E. Mini (1989). "Drug resistance in cancer: an ...
Drug resistanceis a major problem in successfulcancer chemotherapy. Many molecular mechanisms that are responsible for drug resistance are known whereas others have yet to be discovered. Determining the exact mechanism activated in a particular case (clinical or laboratory) is a difficult task. Recently...
M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10, 159–165 (2003). Article PubMed Google Scholar Triller, N., Korosec, P., Kern, I., Kosnik, M. & Debeljak, A. Multidrug resistance in small cell lung ...
Drug Resistance in Cancer: An Overview Cancers have the ability to develop resistance to traditional therapies, and the increasing prevalence of these drug resistant cancers necessitates further... G Housman,S Byler,S Heerboth,... - 《Cancers》 被引量: 321发表: 2014年 Mechanisms and insights ...
drug resistance remains the largest impediment in the quest towards curative cancer treatment, with an estimated 90% of all cancer-related deaths being attributed to chemoresistance. The rapidity with which cancer cells can develop resistance, to both classical chemotherapy and targeted agents, is ...
Cancer Drug Resistance is a peer-reviewed journal led by Editor-in-Chief Godefridus J. (Frits) Peters, covering drug resistance research on breast cancer, lymphatic cancer, hematological malignancies, thyroid cancer, lung cancer, stomach cancer, esophage
Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges for the treatment of drug-resistant ovarian
Intrinsic drug resistance may exist in cancer cells prior to therapies due to the presence of genetic mutation(s) of genes involved in cancer cell growth and/or apoptosis. For example, poorer outcome of cisplatin treatment in gastric cancer patients was found to be associated with HER2 overexpress...
Drug resistance is the main culprit of failure in cancer therapy that may lead to cancer relapse. This resistance mostly originates from rare, but impactful presence of cancer stem cells (CSCs). Ability to self-renewal and differentiation into heterogene